JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 27, 2007; DOI: 10.1124/jpet.107.130237


0022-3565/08/3241-43-49$20.00
JPET 324:43-49, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.130237v1
324/1/43    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciobotaru, V.
Right arrow Articles by Logeart, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciobotaru, V.
Right arrow Articles by Logeart, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure

CARDIOVASCULAR

Effect of Long-Term Heart Rate Reduction by If Current Inhibition on Pressure Overload-Induced Heart Failure in Rats

Vlad Ciobotaru, Michèle Heimburger, Liliane Louedec, Christophe Heymes, Renée Ventura-Clapier, Pierre Bedossa, Brigitte Escoubet, Jean-Baptiste Michel, Jean-Jacques Mercadier, and Damien Logeart

Institut National de la Santé et de la Recherche Médicale U698, Groupe Hospitalier Bichat-Claude Bernard, Paris, France (V.C., M.H., L.L., J.-B.M., J.-J.M., D.L.); Institut National de la Santé et de la Recherche Médicale U689, Hôpital Lariboisière, Paris, France (C.H.); Institut National de la Santé et de la Recherche Médicale U769, Chatenay-Malabry, France (R.V.-C.); Pathology Department, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8149, Assistance Publique-Hôpitaux de Paris, Beaujon Hospital, Clichy, France (P.B.); Institut Nationale de la Sante et de la Recherche Médicale U772, Groupe Hospitalier Bichat-Claude Bernard, Paris, France (B.E.); Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Bichat-Claude Bernard, Service de Physiologie-Explorations Fonctionnelles, Paris, France (B.E., J.-J.M.); and Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Cardiology Department, Paris, France (D.L.)

We investigated the effects of long-term heart rate reduction (HRR) on pressure overload-induced heart failure. Pressure overload of the left ventricle was induced in 21-day-old rats by banding the ascending aorta. HRR was induced for 3 months with ivabradine (n = 44), a selective If current inhibitor, at 10 mg/kg/day, starting 14 days after banding. Thirty-six control banded rats and 16 sham-operated rats received standard chow. Banding resulted in severe left ventricular (LV) hypertrophy (+55% versus shams; p < 0.001) and fibrosis, together with a 34% decrease (p < 0.01) in the LV shortening fraction. Heart rate decreased by 19% in ivabradine-treated rats (p < 0.005 versus controls). Stroke volume increased (by 17%; p < 0.01), whereas cardiac output did not change with HRR. In contrast, HRR resulted in 1) a marked increase in LV filling pressure (p < 0.01) and in atrial, lung, and right ventricular weights (38, 30, and 54%, respectively; p < 0.001); 2) a 50% increase in the incidence of pleural/abdominal effusion (p < 0.001); 3) 7 and 26% increases in LV hypertrophy and fibrosis, respectively (p < 0.05); and 4) a 53% increase in the atrial natriuretic peptide mRNA level compared with controls (p < 0.001). After 3 months of treatment, ivabradine withdrawal normalized the heart rate and reduced LV size and LV filling pressure (p < 0.05). In conclusion, pure longstanding HRR showed no beneficial effect on LV dysfunction in a rat model of pressure overload-induced LV hypertrophy, and it seemed to favor adverse LV remodeling and its congestive consequences.


Received August 15, 2007; accepted September 26, 2007.

Address correspondence to: Dr. Damien Logeart, Cardiology Department, Lariboisiere Hospital, 2 rue Ambroise Pare, 75010 Paris, France. E-mail: damien.logeart{at}lrb.aphp.fr




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
S. Gao, C.-L. Long, R.-H. Wang, and H. Wang
KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function
Cardiovasc Res, April 9, 2009; (2009) cvp099v2.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. Nishio, Y. Sakata, T. Mano, T. Ohtani, Y. Takeda, T. Miwa, M. Hori, T. Masuyama, T. Kondo, and K. Yamamoto
Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats
Eur J Heart Fail, May 1, 2008; 10(5): 446 - 453.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.